Applied Genetic Technologies Corporation (NASDAQ: AGTC) today announced that it has enrolled the first patient of the second cohort in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018July 25, 2018 10:38 AM AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment MilestoneJuly 23, 2018 7:00 AM